Company

Curoverse

Rocket Ship Rating

Rocket Ship Rating: 78 out of 100

Genomic & Biomedical Computing Solutions

Also known as Curoverse Inc

Biotech & therapeutics

Status: Acquiredas of 2026-09-23Source (opens in a new tab)
Business model: B2B
Customers: research institutions and pharmaceutical companies, IT teams managing HPC and cloud infrastructure, clinical testing labs
Legal name: Curoverse Inc

Open relationship map

Claim, correct or request removal

Record updated 29 September 2026

About

Curoverse developed a genomic and biomedical computing platform. Acquired by Veritas Genetics in August 2017.

Funding snapshot

Total raised: $2.2MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
Latest round: Round, $500K2015-03-09

Funding rounds

Round, 2015: $500K2015-03-09, SEC form D sold, 3 investors
Round, 2013: $1.7M2013-08-28, SEC form D sold, 15 investors

About the company

Status notes: Acquired by Veritas Genetics in August 2017.

Products

Web: Arvados
Web: Curoverse Cloud
Web: Curoverse Cluster

Exit

Acquisition: 2017-08